Christie, Alana
Harold C. Simmons Comprehensive Cancer Center · The University of Texas Southwestern Medical Center
3 papers on CoChatORCID 0000-0002-7034-818X
Most cited papers
- Verified
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature
Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment
Cited by 709
- Verified
HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma
Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., et al. (2020) · Clinical Cancer Research
Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatment
Cited by 188
- Verified
Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
Elias, R., Yan, F., Singla, N., Levonyack, N., Formella, J., Christie, A., Kapur, P., Bowman, A. I., Hammers, H. J., Hannan, R., et al. (2019) · Journal of Clinical Oncology
Cancer Immunotherapy and BiomarkersRenal cell carcinoma treatment
Cited by 48
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free